First-Line Immunotherapy Alone Sufficient for Older NSCLC Patients, Study Suggests
(MedPage Today) -- Adding an immune checkpoint inhibitor (ICI) to chemotherapy for older patients with previously untreated advanced non-small cell lung cancer (NSCLC) provided no survival advantage compared with ICI therapy alone, according to... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 7, 2024 Category: Hematology Source Type: news
FDA OKs Amivantamab as First-Line Lung Cancer Treatment
(MedPage Today) -- The FDA approved amivantamab (Rybrevant) plus combination chemotherapy for the first-line treatment of non-small cell lung cancer (NSCLC) in patients whose tumors harbor EGFR exon 20 insertion mutations, as determined by an approved... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 4, 2024 Category: American Health Source Type: news
FDA Approves Amivantamab First-line Indication for NSCLC FDA Approves Amivantamab First-line Indication for NSCLC
Amivantamab plus carboplatin and pemetrexed is now available for first-line treatment of locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 4, 2024 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news
RYBREVANT ® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Approval is based on results from the Phase 3 PAPILLON study, which demonstrated RYBREVANT® plus chemotherapy reduced the risk of disease progression or death by 61 percent versus chemotherapy alone in patients with previously untreated NSCLC with EGFR exon 20 insertion mutations National... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 1, 2024 Category: Pharmaceuticals Tags: FDA TRI Source Type: news
FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications
On March 1, 2024, the FDAapproved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) with carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 1, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Rybrevant (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
RARITAN, New Jersey (March 01, 2024)– Johnson& Johnson (NYSE: JNJ) announced today that following a priority review, the U.S. Food and Drug Administration (FDA) has approved Rybrevant® (amivantamab-vmjw) in combination with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 1, 2024 Category: Drugs & Pharmacology Source Type: news
Bayer receives U.S. FDA Breakthrough Therapy designation for BAY 2927088 for non-small cell lung cancer harboring HER2 activating mutations
Bayer announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for BAY 2927088 for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, and who have received a prior systemic therapy. BAY 2927088 is an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant human epidermal growth factor receptors 2 (HER2), (Source: World Pharma News)
Source: World Pharma News - February 27, 2024 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
Changing the Surgical Paradigm in Oligometastatic NSCLC
(MedPage Today) -- Patients with single-site synchronous oligometastatic non-small cell lung cancer (NSCLC) had better overall survival (OS) when they received surgery for their primary tumor, a retrospective review of nationwide data showed.... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 23, 2024 Category: Hematology Source Type: news
Tislelizumab Plus Chemotherapy Beneficial for Resectable NSCLC
FRIDAY, Feb. 23, 2024 -- For patients with resectable non-small cell lung cancer (NSCLC), neoadjuvant tislelizumab (TIS) plus chemotherapy with adjuvant TIS yields significant benefit in terms of event-free survival (EFS), according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 23, 2024 Category: Pharmaceuticals Source Type: news
2 Top Biotech Stocks That Wall Street Thinks Could Soon Double in Value
Analysts on Wall Street have probably spent more time thinking about the price of stocks than you have, because it's their full-time job. That doesn't mean they're always correct, but it does suggest that there's a lot to learn from understanding their estimates and thinking about how they're…#ginkgobioworks #ginkgo #pfizer #novonordisk #merck #iova #nsclc #fda #iovance #alexcarchidi (Source: Reuters: Health)
Source: Reuters: Health - February 23, 2024 Category: Consumer Health News Source Type: news
Osimertinib Plus Chemo Approved for EGFR-mutated NSCLC Osimertinib Plus Chemo Approved for EGFR-mutated NSCLC
With the new approval, patients now have the option of combination treatment or osimertinib monotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 22, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Tagrisso With the Addition of Chemotherapy Approved in the US for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
19 February 2024 -- AstraZeneca’s Tagrisso has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
The approval... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 19, 2024 Category: Drugs & Pharmacology Source Type: news
Datopotamab Deruxtecan Biologics License Application Accepted in the US for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
Application based on results from the TROPION-Lung01 Phase III trial
If approved, AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan may be the first TROP2-directed antibody drug conjugate for patients with lung cancer
19 February... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 19, 2024 Category: Drugs & Pharmacology Source Type: news
FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 16, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Perioperative Tislelizumab Demonstrates Survival Benefit in NSCLC
(MedPage Today) -- Adding tislelizumab to neoadjuvant chemotherapy followed by adjuvant use of the investigational PD-1 inhibitor improved event-free survival (EFS) in resectable non-small cell lung cancer (NSCLC), a phase III trial from China... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 16, 2024 Category: Hematology Source Type: news
